Celldex Therapeutics Inc.
| NASDAQ: CLDX | Healthcare / Biotechnology / USA |
| 30.21 | +0.9000 | +3.07% | Vol 780.72K | 1Y Perf -20.98% |
| Nov 30th, 2023 16:00 DELAYED |
| BID | 30.50 | ASK | 30.90 | ||
| Open | 29.87 | Previous Close | 29.31 | ||
| Pre-Market | - | After-Market | 30.50 | ||
| - - | 0.29 0.96% |
| Target Price | 64.33 | Analyst Rating | Moderate Buy 1.57 | |
| Potential % | 112.94 | Finscreener Ranking | ★★★★ 52.48 | |
| Insiders Trans % 3/6/12 mo. | -/-/-88 | Value Ranking | ★★★★+ 57.75 | |
| Insiders Value % 3/6/12 mo. | -/-/-98 | Growth Ranking | ★★★+ 54.54 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-98 | Income Ranking | — - | |
| Price Range Ratio 52W % | 30.81 | Earnings Rating | Strong Sell | |
| Market Cap | 1.43B | Earnings Date | 8th Nov 2023 | |
| Alpha | 0.07 | Standard Deviation | 0.57 | |
| Beta | 2.06 |
Today's Price Range 29.3430.25 | 52W Range 22.1148.40 | 5 Year PE Ratio Range -7.10-0.8000 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 5.37% | ||
| 1 Month | 28.17% | ||
| 3 Months | 4.86% | ||
| 6 Months | -5.98% | ||
| 1 Year | -20.98% | ||
| 3 Years | 38.77% | ||
| 5 Years | 571.33% | ||
| 10 Years | -92.74% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -17.95 | |||
ROE last 12 Months | -29.63 | |||
ROA (5Y Avg) | -10.97 | |||
ROA last 12 Months | -27.92 | |||
ROC (5Y Avg) | -41.93 | |||
ROC last 12 Months | -26.87 | |||
Return on invested Capital Q | -7.46 | |||
Return on invested Capital Y | -4.67 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 4.40 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -19.40 | ||||
| 5.98 | ||||
| 2.84K | ||||
| - | ||||
| -24.70 | ||||
| -2.06 | ||||
| 6.49 | ||||
| 7.33 | ||||
| 1.75B | ||||
| Forward PE | -8.33 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 19.90 | ||||
| 20.50 | ||||
| 0.01 | ||||
| 0.01 | ||||
| - | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -9 257.50 | ||||
| -8 979.20 | ||||
| -2 158.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 744.00K | ||||
| 0.02 | ||||
| -4.54 | ||||
| -13.62 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.67 | -0.81 | -20.90 |
| Q02 2023 | -0.65 | -0.65 | 0.00 |
| Q01 2023 | -0.63 | -0.62 | 1.59 |
| Q04 2022 | -0.59 | -0.56 | 5.08 |
| Q03 2022 | -0.57 | -0.57 | 0.00 |
| Q02 2022 | -0.43 | -0.58 | -34.88 |
| Q01 2022 | -0.46 | -0.49 | -6.52 |
| Q04 2021 | -0.42 | -0.43 | -2.38 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | -0.84 | -21.74 | Negative |
| 12/2023 QR | -0.69 | -1.47 | Negative |
| 12/2023 FY | -2.90 | -9.85 | Negative |
| 12/2024 FY | -3.44 | -12.42 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | -0.67 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 780.72K |
| Shares Outstanding | 47.26K |
| Shares Float | 45.52M |
| Trades Count | 8.86K |
| Dollar Volume | 23.40M |
| Avg. Volume | 784.26K |
| Avg. Weekly Volume | 586.72K |
| Avg. Monthly Volume | 1.11M |
| Avg. Quarterly Volume | 658.95K |
Celldex Therapeutics Inc. (NASDAQ: CLDX) stock closed at 30.21 per share at the end of the most recent trading day (a 3.07% change compared to the prior day closing price) with a volume of 780.72K shares and market capitalization of 1.43B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 130 people. Celldex Therapeutics Inc. CEO is Anthony S. Marucci.
The one-year performance of Celldex Therapeutics Inc. stock is -20.98%, while year-to-date (YTD) performance is -32.22%. CLDX stock has a five-year performance of 571.33%. Its 52-week range is between 22.11 and 48.4, which gives CLDX stock a 52-week price range ratio of 30.81%
Celldex Therapeutics Inc. currently has a PE ratio of -19.40, a price-to-book (PB) ratio of 5.98, a price-to-sale (PS) ratio of 2 839.28, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -27.92%, a ROC of -26.87% and a ROE of -29.63%. The company’s profit margin is -%, its EBITDA margin is -8 979.20%, and its revenue ttm is $744.00 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Celldex Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.67 for the next earnings report. Celldex Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Celldex Therapeutics Inc. is Moderate Buy (1.57), with a target price of $64.33, which is +112.94% compared to the current price. The earnings rating for Celldex Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Celldex Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Celldex Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 27.57, ATR14 : 1.70, CCI20 : 105.88, Chaikin Money Flow : -0.22, MACD : 0.90, Money Flow Index : 52.30, ROC : 12.14, RSI : 61.60, STOCH (14,3) : 99.32, STOCH RSI : 1.00, UO : 54.23, Williams %R : -0.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Celldex Therapeutics Inc. in the last 12-months were:
Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.
CEO: Anthony S. Marucci
Telephone: +1 908 200-7500
Address: 53 Frontage Road, Hampton 08827, NJ, US
Number of employees: 130
TipRanks News for CLDX
Mon, 06 Nov 2023 13:01 GMT Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Celldex (CLDX) and Cytokinetics (CYTK)
- TipRanks. All rights reserved.Mon, 06 Nov 2023 13:01 GMT Celldex (CLDX) Gets a Buy from Cantor Fitzgerald
- TipRanks. All rights reserved.Fri, 14 Jul 2023 09:40 GMT Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), RegenXBio (RGNX) and Oculis Holding (OCS)
- TipRanks. All rights reserved.
